This Is MS Multiple Sclerosis Community: Knowledge & Support

Newer compounds impacting on current MS disease modifying drugs




While Biogen Idec's Avonex and Teva's Copaxone continue to capture the majority of multiple sclerosis (MS) patients first starting on a disease-modifying agent (DMA), the introduction of Novartis' Gilenya, the only oral DMA currently on the market, appears to have impacted the average length of the time that patients remain on their first-line therapy before a switch may be initiated.

Gilenya, typically prescribed as a second or later-line DMA, has also negatively impacted the overall market share of certain DMAs compared to the 2010 audit fielded prior to the Gilenya launch, with Pfizer / EMD Serono's Rebif and Biogen Idec's Avonex, taking the greatest hit.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... pageid/683

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis